William L. Perry
Lilly Research Laboratories
Lilly Corporate Center
Indianapolis
IN 46285
USA
Name/email consistency: high
- Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Perry, W.L., Shepard, R.L., Sampath, J., Yaden, B., Chin, W.W., Iversen, P.W., Jin, S., Lesoon, A., O'Brien, K.A., Peek, V.L., Rolfe, M., Shyjan, A., Tighe, M., Williamson, M., Krishnan, V., Moore, R.E., Dantzig, A.H. Cancer Res. (2005)
- The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. Perry, W.L., Weitzman, A. Clin. Adv. Hematol. Oncol (2005)
- JavaScript DNA translator: DNA-aligned protein translations. Perry, W.L. BioTechniques (2002)